Understanding how changes in tubulin affect nerve damage from chemotherapy
Investigating the Pathogenic Role of Tubulin Post-translational Modifications in CIPN
This study is looking into how changes in a protein called tubulin might cause the painful nerve damage that many cancer patients experience from chemotherapy, with the goal of finding new ways to help prevent or ease this side effect.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10803901 on NIH RePORTER |
What this research studies
This research investigates the role of tubulin modifications in causing chemotherapy-induced peripheral neuropathy (CIPN), a common and painful side effect experienced by many cancer patients undergoing treatment. The study aims to uncover the underlying mechanisms by which certain chemotherapy drugs lead to nerve damage, focusing on how changes in tubulin, a key protein in nerve cells, may contribute to this condition. By analyzing the effects of these modifications, researchers hope to identify potential targets for new treatments that could alleviate or prevent CIPN.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are undergoing chemotherapy and experiencing symptoms of peripheral neuropathy.
Not a fit: Patients who are not undergoing chemotherapy or those who do not experience peripheral neuropathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better treatments for patients suffering from nerve damage caused by chemotherapy.
How similar studies have performed: Previous research has shown that targeting tubulin and its modifications can be effective in understanding and potentially treating neuropathic pain, suggesting a promising avenue for this investigation.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Bartolini, Francesca — Columbia University Health Sciences
- Study coordinator: Bartolini, Francesca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.